Contract announcement

Contract announcement

Physiomics plc (AIM: PYC), the consultancy using mathematical models to support the development of drug treatment regimens and personalised medicine solutions, is pleased to announce that it has been awarded a further contract by existing client Bicycle Therapeutics (“Bicycle”).  The project relates to an undisclosed program and is expected to be completed in the Company’s current financial year.

 

Physiomics CEO, Dr Jim Millen, commented: “We are delighted that Bicycle has chosen us to support this new project.  Physiomics has been working with Bicycle since 2019 and has been involved in various Bicycle programs spanning discovery through clinical development.  We look forward to working with this valued client once again.”

 

 

Enquiries:

 

Physiomics plc                                                  

Dr Jim Millen, CEO

+44 (0)1865 784 980

 

Hybridan LLP (broker)

Claire Louise Noyce

+44 (0) 203 764 2341

 

Strand Hanson Ltd (NOMAD)

James Dance & James Bellman

+44 (0)20 7409 3494

 

 

Notes to Editor

 

About Physiomics

 

Physiomics plc (AIM: PYC) is an oncology consultancy using mathematical models to support the development of cancer treatment regimens and personalised medicine solutions. The Company’s Virtual Tumour™ technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Physiomics’ technologies have been confirmed by over 100 projects, involving over 40 targets and 70 drugs, and has worked with clients such as Merck KGaA, Astellas, Merck & Co and Bicycle Therapeutics.